Marie Lund

Marie Lund serves as Clinical Associate Professor in the Department of Clinical Medicine at the University of Copenhagen's Faculty of Health and Medical Sciences, specializing in Clinical Pharmacology. Her research focuses on drug safety and pharmacovigilance, particularly examining cardiovascular complications associated with cancer therapies and electrolyte disorders from diuretic treatments.

Her primary research interests include clinical pharmacology, oncology, cardiovascular medicine, and pharmacoepidemiology. Lund investigates critical intersections between cancer treatments and cardiovascular health, with emphasis on aromatase inhibitors' cardiotoxic effects in breast cancer patients, LDL-cholesterol dynamics during hormone therapy, and thiazide-induced hyponatremia mechanisms. Her work employs nationwide cohort studies and real-world data analysis to address drug safety questions with direct clinical implications.

Lund's recent publications reveal strong trends in pharmacoepidemiology and translational pharmacology, with significant contributions to understanding drug-induced electrolyte imbalances and cardiovascular risks in cancer therapy. Her research spans from basic pharmacogenomics (GWAS studies on sodium regulation) to regulatory science (comparative analysis of drug approval pathways), demonstrating methodological breadth across observational studies, predictive modeling, and policy-relevant research.

Her collaborative network includes major Danish health registries and international research groups, with publications appearing in high-impact journals including The Lancet Oncology, JAMA Oncology, and Annals of Internal Medicine. Lund's work has generated substantial scientific discussion, evidenced by media coverage across 14 news outlets and social media engagement from hundreds of researchers.